/ /

ModernMedicine Resource Center More Topics
 
Click here to learn about the prevalence of HSDD and hear from Key Opinion Leaders about its effect on premenopausal women.
 

Sexual dysfunction resource center

Talking about female sexual dysfunction in specific patient populationsFor particular groups of women, reluctance to talk about sexual difficulties may be enhanced by perceived societal judgements and misconceptions.
Talking to women about sexual dysfunction: Just do it!Female sexual dysfunction is not rare. In the United States, 44% of women are reported to experience some form of sexual dysfunction and 12% of these women report distress associated with dysfunction. Despite this high prevalence, many women never talk to their providers about their sexual difficulties or concerns and many providers fail to broach the topic with their patients.
Establishing a diagnosis of female sexual dysfunctionAn algorithm for determining whether a woman has female sexual dysfunction and which one she may have.
Types of Female Sexual DysfunctionDespite its prevalence and adverse effect on women’s quality of life, female sexual dysfunction is often not addressed for a myriad of reasons.
How prevalent is Hypoactive Sexual Disorder (HSDD)?Learn about the prevalence of HSDD and hear from Key Opinion Leaders about its effect on premenopausal women.
Effective management of antidepressant-induced sexual dysfunctionSmall studies suggest effective strategies, but more trials are needed.
Taking Sides: Should ob/gyns prescribe flibanserin for their patients?
Taking Sides: Should ob/gyns prescribe flibanserin for their patients?A look at the pros and cons of this new drug for women with low sexual desire.
Flibanserin: Risk potential vs. possible benefitBecause of concerns about adverse effects, training through the Addyi REMS program is required for prescribers and pharmacies that want to participate in the medication use process for this drug.